Last reviewed · How we verify
NCT04799080
Chemotherapy-induced Peripheral Neuropathy (CIPN) on Motor and Sensory Function
trial in Cancer in 72 participants. Completed in 15 May 2022.
15 March 2022
Quick facts
| Lead sponsor | Izmir Bakircay University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 72 |
| Start date | 6 March 2021 |
| Primary completion | 15 March 2022 |
| Estimated completion | 15 May 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Cancer — all drugs for Cancer →
- Chemotherapy-induced Peripheral Neuropathy — all drugs for Chemotherapy-induced Peripheral Neuropathy →
- Chemotherapeutic Toxicity — all drugs for Chemotherapeutic Toxicity →
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Izmir Bakircay University
Who can join
Adults 18 to 85, any sex, with Cancer or Chemotherapy-induced Peripheral Neuropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
As cancer survival rates have been increased due to technological developments and early detection strategies, there has been been a growing need to assess the effect of long-term complications and adverse effects upon patients' functionality and quality of life. Chemotherapy, which is accepted to be the body of systemic adjuvant therapy is attributed to long-term survival, yet some side effects such as sarcopenia, loss of muscle strength and functional capacity, fatigue, and sensory disturbances due to the neurotoxic effects have been well known. Chemotherapy-induced peripheral neuropathy (CIPN) is a condition that is characterized by main loss of cutaneous sensation especially in the distal part of the extremities. CIPN affects approximately 30-40% of patients with cancer undergoing chemotherapy. Loss of sensation in distal sides of upper and lower extremities may cause not only deterioration of fine hand skills but also loss of balance and thereby one's mobility and independence are detrimentally affected. Thus, this study is aimed to assess CIPN in patients with cancer undergoing chemotherapy in a longitudinal design by assessing the cutaneous function of the sensory nerves and related effect of motor function.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Assessment of sensorimotor and strength related function of breast cancer patients during systemic drug therapy: a prospective observational study.
Tuğral A, Arıbaş Z, Akyol M, Bakar Y. · · 2023 · cited 6× · PMID 37838686 · DOI 10.1186/s12885-023-11494-x -
Assessing Fine Motor and Sensory Functions In Patients With Breast Cancer At Risk for Chemotherapy Induced Peripheral Neuropathy (CIPN)
Tuğral A, Arıbaş Z, Akyol M, Bakar Y. · · 2022 · DOI 10.21203/rs.3.rs-1419318/v1
Verify or expand the search:
- PubMed search for NCT04799080
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other Izmir Bakircay University trials
Trials by the same sponsor.
- NCT07095764 — Effects of In-Hospital Cardiac Rehabilitation and Manual Lymphatic Drainage in Acute Decompensated Heart Failure · NA · completed
- NCT06579131 — Seating Posture and Its Relation to Pain · not yet recruiting
- NCT07377448 — Insulin Use and Respiratory Muscle Strength in Type 2 Diabetes · completed
- NCT06946082 — The Effect of Upper Extremity Motor Function, Trunk Control and Motor Imagery Ability on Turkish Language Skills in Indi · recruiting
- NCT07023224 — Reliability and Validity Study of the Turkish Version of the Parkinson's Disease Dyskinesia Scale (PDYS-26) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04799080 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Izmir Bakircay University
- Last refreshed: 1 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04799080.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing